13862 studies found for:    Canada
Show Display Options
Rank Status Study
1 Active, not recruiting Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Conditions: Cardiovascular Disease;   Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide;   Drug: Placebo
2 Completed
Has Results
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
Condition: Heart Decompensation
Interventions: Drug: Nesiritide;   Drug: Placebo
3 Recruiting Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation
Conditions: Heart Disease;   Congestive Heart Failure;   Atrial Fibrillation
Interventions: Device: Optimal Medical therapy plus ICD;   Device: Optimal Medical therapy plus CRT/ICD
4 Active, not recruiting Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
Condition: Chronic Kidney Disease
Intervention:
5 Completed
Has Results
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin;   Drug: Dapagliflozin placebo;   Drug: Metformin
6 Completed
Has Results
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Ticagrelor;   Drug: Clopidogrel
7 Completed Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: Atrasentan
8 Completed
Has Results
ESPRIT Study in Hypogonadal Men
Condition: Hypogonadism
Intervention: Drug: AndroGel (testosterone gel) 1%
9 Completed A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: aleglitazar
10 Recruiting Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Biological: evolocumab (AMG 145) and standard of care;   Other: Standard of care
11 Active, not recruiting
Has Results
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: trastuzumab;   Drug: docetaxel;   Drug: lapatinib ditosylate;   Drug: paclitaxel
12 Unknown  Eligard Observational Registry for Patients With Prostate Cancer
Condition: Cancer of the Prostate
Intervention:
13 Completed Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
Condition: Hypertriglyceridemia
Interventions: Dietary Supplement: CaPre™;   Drug: Lipid Lowering Medication
14 Completed Resynchronization/Defibrillation for Ambulatory Heart Failure Trial
Condition: Heart Failure, Congestive
Interventions: Device: Optimal Medical Therapy plus ICD;   Device: Optimal Medical Therapy plus CRT/ICD
15 Completed
Has Results
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Condition: Asthma
Interventions: Drug: Ciclesonide;   Drug: Usual Care Inhaled Glucocorticosteroids
16 Active, not recruiting Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Conditions: Psoriasis;   Arthritis, Psoriatic
Interventions: Biological: ustekinumab;   Biological: Biological therapies other than infliximab and ustekinumab;   Drug: conventional systemic agents;   Biological: infliximab
17 Completed OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
18 Terminated Study In Asthma Control
Condition: Asthma
Intervention: Drug: salmeterol xinafoate/fluticasone propionate
19 Recruiting Observational Study of Golimumab Intravenous Infusion
Condition: Rheumatoid Arthritis
Intervention: Biological: Golimumab Intravenous
20 Recruiting A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Conditions: Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
Interventions: Biological: Denosumab;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years